| Symproic (naldemedine) / Shionogi, Collegium Pharma |
NCT01122030: Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain |
|
|
| Completed | 2 | 72 | US | Naldemedine, S-297995, Symproic®, Placebo | Shionogi | Opioid Induced Bowel Dysfunction | 02/11 | 03/11 | | |
NCT01443403: A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy |
|
|
| Completed | 2 | 244 | US | Placebo, Naldemedine, S 297995, Symproic® | Shionogi | Opioid-induced Constipation | 08/12 | 08/12 | | |
NCT04355169: A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection |
|
|
| Terminated | 2 | 2 | US | Naldemedine, S-297995, Placebo | Shionogi | Postoperative Gastrointestinal Dysfunction | 01/21 | 01/21 | | |
NCT06334198: The Effect of Naldemedine on Opioid-induced Bowel Dysfunction |
|
|
| Recruiting | 2 | 20 | Europe | Naldemedine, Placebo, Tramadol | Asbjørn Mohr Drewes | Opioid-Induced Bowel Dysfunction, Constipation | 03/25 | 03/25 | | |
| Recruiting | 1/2 | 24 | Europe | Naldemedine, Rizmoic | Shionogi, Shionogi & Co. Ltd | Opioid-Induced Constipation (OIC) | 08/24 | 08/24 | | |
